Washington Post

Abbott Laboratories presented atrasentan, which has the trade name Xinlay, as a treatment for men with an advanced stage of prostate cancer that has spread to the bone. But the FDA's Oncologic Drugs Advisory Committee voted unanimously against recommending it.

More...

Takeover of Indigenous Garifuna Community Hospital

Menstruation Is Fast Becoming Optional

Rare Disease Traced to Sperm Donor

Crohn's Disease Drug Cleared for Children

5-Month-Old Girls in ICU After Separation

Coroner: Peanut Kiss Didn't Cause Death

Feds Probe Kidney Transplant Program

Supermarkets Urge Families to Dinner Table